# PK Assessment of Tacrolimus Exposure Before and After a Switch From Twice Daily Immediate-release (Prograf®) to Once-daily Prolonged Release Tacrolimus (Envarsus®)

> **NCT02882828** · PHASE4 · COMPLETED · sponsor: **University Hospital, Limoges** · enrollment: 134 (actual)

## Conditions studied

- Allograft

## Interventions

- **DRUG:** switched from Prograf® to Envarsus®

## Key facts

- **NCT ID:** NCT02882828
- **Lead sponsor:** University Hospital, Limoges
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-10
- **Primary completion:** 2020-03
- **Final completion:** 2020-03
- **Target enrollment:** 134 (ACTUAL)
- **Last updated:** 2025-11-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02882828

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02882828, "PK Assessment of Tacrolimus Exposure Before and After a Switch From Twice Daily Immediate-release (Prograf®) to Once-daily Prolonged Release Tacrolimus (Envarsus®)". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT02882828. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*